Prostate Cell News Volume 5.22 | Jun 20 2014

Interruption of KLF5 Acetylation Converts Its Function from Tumor Suppressor to Tumor Promoter in Prostate Cancer Cells
KLF5 possesses both tumor suppressing and tumor promoting activities, though the mechanism controlling these opposing functions is unknown. Scientists tested whether the acetylation status of KLF5 also determines its opposing functions in tumorigenesis using the PC-3 and DU 145 prostate cancer cell lines. [Int J Cancer] Abstract

Deletion of Atbf1/Zfhx3 in Mouse Prostate Causes Neoplastic Lesions, Likely by Attenuation of Membrane and Secretory Proteins and Multiple Signaling Pathways
Investigators examined the role of ATBF1 in prostatic carcinogenesis by specifically deleting Atbf1 in mouse prostatic epithelial cells. It also examined the effect of Atbf1 deletion on gene expression and signaling pathways in mouse prostates. [Neoplasia] Full Article

Deficiency of ERb and Prostate Tumorigenesis in FGF8b Transgenic Mice
The authors studied the effect of estrogen receptor beta (ERb) deficiency on prostate tumorigenesis by crossing ERb knockout mice with prostate-targeted fibroblast growth factor 8b (FGF8b) transgenic mice. [Endocr Relat Cancer] Abstract

Regulation of GLUT Transporters by Flavonoids in Androgen-Sensitive and Insensitive Prostate Cancer Cells
Researchers investigated the regulation of some glucose transporters -GLUT1 and GLUT4- in both androgen-sensitive and insensitive prostate cancer cells by four structurally different flavonoids (i.e. genistein, phloretin, apigenin and daidzein). [Endocrinology] Abstract

Apoptotic Death of Prostate Cancer Cells by a Gonadotropin-Releasing Hormone-II Antagonist
Scientists developed the gonadotropin-releasing hormone-II antagonist, SN09-2, to inhibit proliferation and stimulate the autophagic death of various PC3 prostate cancer cells, including androgen-independent cells. [PLoS One] Full Article

ERBB2 Increases Metastatic Potentials Specifically in Androgen-Insensitive Prostate Cancer Cells
To evaluate and define the role of the ERBB2/RAS pathway in prostate cancer metastasis, investigators observed the impact of ERBB2– or RAS-overexpression on the metastatic potentials for four prostate cancer cell lines derived from tumors with different androgen sensitivities. [PLoS One] Full Article

Synthesis and Cytotoxic Effect on Cancer Cell Lines and Macrophages of Novel Progesterone Derivatives Having an Ester or a Carbamate Function at C-3 and C-17
Researchers report the cytotoxic effect on human cancer cells of two series of novel progesterone derivatives; the first containing an aromatic ester or a carbamate functions both linked to C-3 on the pregn-4,16-diene-6,20-dione skeleton. In the second series, both functional groups (ester and carbamate) are bound to C-17 on the pregn-4,6-diene-3,20-dione scaffold. [Eur J Med Chem] Full Article

CLINICAL RESEARCH

Feasibility Study of a Randomized Controlled Trial to Compare (Deferred) Androgen Deprivation Therapy and Cryotherapy in Men with Localized Radiation-Recurrent Prostate Cancer
Investigators aimed to determine the feasibility of randomizing men with radiation recurrent prostate cancer for treatment with androgen deprivation therapy and salvage prostate cryoablation. [Br J Cancer] Abstract

Comparative Effects of Two Different Forms of Selenium on Oxidative Stress Biomarkers in Healthy Men: A Randomized Clinical Trial
Results from previous clinical trials suggest that selenium-enriched yeast (SY) but not selenomethionine (SeMet) may be effective at reducing prostate cancer risk; therefore, scientists directly compared the effects of SeMet and SY on prostate cancer relevant biomarkers in men. [Cancer Prev Res (Phila)] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Takeda Announces Termination of Orteronel (TAK-700) Development for Prostate Cancer in Japan, U.S.A. and Europe
Takeda Pharmaceutical Company Limited announced that it has voluntarily decided to end the development program for orteronel (TAK-700) for prostate cancer [Takeda Pharmaceutical Company Ltd.] Press Release

GenomeDx Expands Insurance Coverage for Decipher^® Prostate Cancer Test through Contract with Prime Health Services
GenomeDx Biosciences announced that it has entered into a contractual agreement as a participating provider with Prime Health Services to provide diagnostic laboratory testing services. GenomeDx, which discovered and developed the Decipher^® Prostate Cancer Classifier, will provide laboratory services, making the Decipher test available to members of the Prime Healthcare network, which includes 9 million covered lives. [GenomeDx Biosciences] Press Release

From our sponsor: Learn about assays for cord blood. Download the free technical bulletin.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the prostate cell community.

NEW Postdoctoral Position – Role of Chromatin in Prostate Cancer (University of Victoria)

NEW Scientist – Prostate Cell Research (STEMCELL Technologies Inc.)

NEW Scientist – Pluripotent Stem Cell Media Development: High Throughput Screening (STEMCELL Technologies Inc.)

NEW Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Postdoctoral Position – Prostate Cancer Aggressiveness and Progression in Prostate Cancer (Roswell Park Cancer Institute)

PhD Studentship – Prostate Cancer Research (Cardiff University)

Postdoctoral Fellow – Prostate Cancer Research (Henry Ford Hospital)

Research Fellow – Molecular Mechanisms of Prostate Cancer (Northwestern University- Feinberg School of Medicine)

Postdoctoral Research Associate – Prostate Cancer Research (Medical University of South Carolina)

Postdoctoral Researcher – Therapeutic Targets for Cancer Treatment (Sanford Burnham Medical Research Institute)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.